Recent Developments in the Global Apheresis Market:

# In July 2019, Baxter International Inc. (US) launched the PrisMax system in the US.

# In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.

# In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (China). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.

# In August 2017, Fresenius Medical Care (Germany) acquired NxStage Medical, Inc. (US). This acquisition enabled Fresenius Medical Care to further expand its presence in the renal care and critical care area.

Major Growth Influencing Factors:

The market for apheresis is primarily driven by the rising prevalence of chronic diseases and the growing number of trauma and injury cases, the increasing demand for source plasma from biopharmaceutical companies, the rising demand for blood components and growing concerns regarding blood safety, the increase in the number of complex surgical procedures, and the favorable reimbursement for apheresis procedures.

However, the high cost of apheresis devices therapeutic apheresis procedures and installation of apheresis devices through the rental model, fewer blood donations using apheresis due to lack of awareness, and the stringent donor recruitment criteria are factors expected to limit market growth to a certain extent in the coming years.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950

Expected Revenue Gains:

The global apheresis market is expected to reach USD 2.7 billion by 2025 from an estimated value of USD 1.7 billion in 2019, growing at a CAGR of 8.1% during the forecast period.

Key Market Players:

The key players in the global apheresis market are Terumo BCT, Inc. (US), Fresenius SE Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), and Nikkiso Co., Ltd. (Japan).

Different Growth Strategies Adopted by Them:

The key players of this market focus on increasing their market presence with the adoption of both organic and inorganic growth strategies. These include product launches, agreements, partnerships, collaborations, and acquisitions.

Terumo BCT, Inc. (US) was the leading player in the apheresis market and accounted for the largest share in 2018. The company is known for its diversified product offerings in the field of apheresis. Terumo’s products include the Spectra Optia, COBE Spectra, and Trima Accel, and these are widely adopted by blood centers, blood component providers, hospitals, and transfusion centers for donor therapeutic apheresis purposes. The company has a significant global footprint owing to its strong sales and distribution network.

Fresenius SE Co. KGaA (Germany) Fresenius is a global player in the apheresis market, with wide geographic coverage. The company has maintained its leading position in the market through its strong distribution networks across the Asia Pacific, North America, Europe, Latin America, and the Middle East Africa. The company offers apheresis systems and related disposables for both donor therapeutic apheresis through its Fresenius Kabi and Fresenius Medical Care business segments. The company strengthens its business operations by expanding its presence in emerging markets. For instance, in 2016, Fresenius introduced the AmiCORE apheresis device in Malaysia, Thailand, and Vietnam. It has a strong product portfolio, and its CE-approved products have helped it in further enhancing its presence in the apheresis market.

Haemonetics Corporation (US) Haemonetics Corporation is a key competitor in the apheresis market for both the collection of cells and therapeutic apheresis. The company has a strong product profile in automated blood component collection. Haemonetics also has a wide geographic presence across the US, Europe, Japan, and Asia, which enables it to cater to its customers across the globe. Around 62% of the company’s revenue is generated from the US market. Haemonetics also focuses on high-growth emerging countries in order to increase its share in the apheresis market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=950

North America accounted for the largest share of the apheresis market in 2018

The apheresis market is segmented into five major regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East Africa. In 2018, North America accounted for the largest share of the apheresis market. The large share of this region can be attributed to easier access to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.